Dr. Steven Quay Joins Hearing on Virus Research Funding

In front of the Senate Homeland Security and Governmental Affairs Subcommittee on Emerging Threats, Dr. Steven Quay discusses the risks and benefits of gain of function research and how it connects to our current pandemic; Covid-19.

This video has been edited to only show questions and responses directed at Dr. Quay. We do not own this video and have only published it here for educational purposes. To view the video in it’s entirety, please visit the CSPAN website here:

https://www.c-span.org/video/?522133-1/hearing-virus-research-funding

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

Explore innovative oral drug delivery strategies for breast cancer prevention with Dr. Steven Quay, CEO of Atossa Therapeutics, focusing on reducing breast density and cancer risk.